Walleye Capital’s ProQR Therapeutics PRQR Stock Holding History

Walleye Capital’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$984K	Buy	607,529 +15,744	+3%	+$25.8K	﹤0.01%	2089
2025 Q4	$1.2M	Buy	591,785 +59,808	+11%	+$140K	﹤0.01%	2291
2025 Q3	$1.13M	Hold	531,977	–	–	﹤0.01%	1990
2025 Q2	$1.09M	Buy	531,977 +28,413	+6%	+$46.2K	﹤0.01%	1982
2025 Q1	$670K	Buy	503,564 +52,261	+12%	+$111K	﹤0.01%	2314
2024 Q4	$1.2M	Buy	+451,303	New	+$1.43M	﹤0.01%	2219
2020 Q1	–	Sell	-11,393	Closed	-$113K	–	1501
2019 Q4	$113K	Buy	+11,393	New	+$88.7K	0.01%	1329

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Walleye Capital's PRQR Position: Q1 2026 in Review

Walleye Capital increased its ProQR Therapeutics (PRQR) stake by 2.7% in Q1 2026, buying an estimated $25.8K and bringing the position to 607,529 shares worth $984K. The position accounts for ﹤0.01% of the portfolio, ranked #2089.

Walleye Capital first reported a position in PRQR in Q4 2019 and has held it in 7 quarters since. The position peaked at $1.2M in Q4 2024. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

Walleye Capital held 607,529 shares of ProQR Therapeutics worth $984K as of Q1 2026.
Walleye Capital bought 15,744 ProQR Therapeutics shares in Q1 2026, an estimated $25.8K.
ProQR Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2089 holding.
Walleye Capital first reported a position in ProQR Therapeutics in Q4 2019 and has held it in 7 quarters since.
Walleye Capital's ProQR Therapeutics position peaked at $1.2M in Q4 2024.
69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.